查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451899

學名藥市場：2024-2032 年全球產業趨勢、佔有率、規模、成長、機會與預測

Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2023年全球腫瘤學名藥市場規模達293億美元。展望未來， IMARC Group預計到2032年市場規模將達到459億美元，2024-2032年複合年成長率（CAGR）為4.98%。由於過度吸煙和飲酒導致癌症患病率不斷上升，對開發新藥的研究投資不斷增加，以及對簡化藥品生產流程的嚴格法規的執行日益嚴格，推動該市場正在穩步成長。

學名藥市場分析：

市場成長與規模：在癌症盛行率不斷上升以及對具有成本效益的治療方案的需求不斷成長的推動下，學名藥市場正在經歷穩定成長。

主要市場促進因素：主要促進因素包括癌症盛行率上升、品牌腫瘤藥物的專利到期、政府控制醫療成本的措施以及藥品製造技術的進步。

技術進步：持續創新正在增強品質控制、簡化製造流程以及改善學名藥的配方和給藥系統。

產業應用：學名藥主要用於各種癌症類型的癌症治療，使其成為癌症治療的重要組成部分。它們提供具有成本效益的品牌藥物替代品，增加患者的可近性。

主要市場趨勢：主要趨勢包括腫瘤學中擴大採用生物相似藥、個人化醫療方法以及遠距醫療和遠距醫療保健服務對藥物輸送的影響。這些趨勢反映了不斷變化的患者需求和醫療保健實踐。

地理趨勢：由於癌症盛行率高、監管框架嚴格以及對成本控制的重視，北美地區的學名藥市場呈現顯著成長。由於醫學研究業務投資的增加，亞太地區也出現了重大發展。

競爭格局：市場競爭格局為多家製藥公司積極從事腫瘤學學名藥的研發和生產。策略夥伴關係和收購是加強市場地位的常見策略。

挑戰與機會：挑戰包括應對複雜的監管流程、確保產品品質和安全以及應對競爭。然而，這些挑戰也為擴大產品組合、滿足個人化癌症治療的需求以及進入醫療保健需求未滿足的新興市場提供了機會。總體而言，市場為能夠有效應對這些挑戰的參與者提供了巨大的成長潛力。

學名藥市場趨勢：

癌症病例增加

全球癌症病例的增加是推動市場成長的關鍵因素之一。癌症診斷的增加正在導致製藥業內的一系列發展和變革，特別是在學名藥領域。這些由癌症發病率上升所推動的轉變是多方面的，具有深遠的影響，有助於提高非專利腫瘤藥物的可及性和有效性。隨著癌症成為發病率和死亡率的主要原因，提供具有成本效益且可靠的治療方案至關重要。腫瘤學學名藥通常比品牌藥更實惠，非常適合滿足這一需求，並為不同社會經濟背景的患者提供易於使用的解決方案。它們的經濟性和可近性使它們成為對抗癌症不可或缺的工具，確保患者得到及時和充分的照顧。醫療保健系統壓力的緩解提高了癌症治療的整體效率和效果，最終使患者受益。

政府措施和法規

政府監管機構負責監督學名藥腫瘤藥物的核准和市場准入。他們制定了嚴格的標準，在批准之前評估這些藥物的安全性和有效性。這些標準對於確保學名藥成為品牌藥的可靠且有效的替代品至關重要。與專利到期和市場獨佔期相關的政府政策顯著影響學名藥的可用性。當品牌腫瘤藥物的專利到期時，監管機構可能會批准學名藥進入市場。這個過程以法律框架為指導，鼓勵製藥業的競爭和可負擔性。監管機構負責監督藥物警戒計劃，以監測和評估學名藥上市後的安全性。這些機構也執行品質控制標準，以維持藥物品質和純度的一致性，確保患者接受安全有效的治療。此外，各國管理機構正在提供研究資助或稅收優惠等激勵措施，以鼓勵製藥公司投資學名藥的開發。

製造技術進步

學名藥生產的不斷進步正在支持市場的成長。連續製造和即時監控系統等先進製造技術正在改善學名藥的品質控制。這些系統使製藥公司能夠保持一致的產品質量，降低影響患者治療結果的變化風險。這種增強的品質保證增強了人們對學名藥有效性的信心。自動化和機器人技術正在簡化學名藥的製造流程。效率的提高可以提高這些藥物的產量、降低生產成本並加快上市時間。技術進步也擴大了製造業務的可擴展性。這使得學名藥製造商能夠根據市場需求更靈活地調整產量。藥物配方和輸送系統的進步正在促進創新學名藥腫瘤藥物產品的開發。這些技術有潛力提高藥物療效、減少副作用並提高患者依從性，所有這些都是癌症治療的關鍵因素。

專利到期和具有成本效益的解決方案

幾種品牌腫瘤藥物的專利到期為學名藥製造商帶來了機會。當創新癌症療法的專利到期時，學名藥製造商可以進入市場，提供成本更低的替代品。這種競爭不僅減輕了病患的經濟負擔，也有助於控制醫療成本。負擔得起的學名藥腫瘤藥物的可用性確保更多患者能夠獲得治療，從而推動市場成長。

監管支持和批准途徑

監管機構正在實施學名藥的快速核准途徑。此外，各種政府措施和政策鼓勵學名藥的開發和生產。這些監管支持為學名藥製造商創造了有利的環境。一些監管機構也為學名藥腫瘤藥物的審查和批准提供快速途徑，特別是當需要加強競爭或相關藥物來解決未滿足的醫療需求時。這些途徑旨在簡化核准流程並促進及時進入市場。學名藥製造商可能會面臨來自尋求擴大其獨佔權的創新公司的專利挑戰。專利訴訟和挑戰在監管環境中發揮重要作用，因為專利糾紛的解決可以影響學名藥市場進入的時間。

個性化醫療的需求

基因組學和生物標記研究的進步使得人們能夠更深入地了解癌症的分子機制。這些知識可以識別與不同類型癌症相關的特定基因改變和生物標記，為標靶治療的開發鋪平道路。腫瘤學中的個人化醫療通常涉及使用標靶療法，旨在根據特定的分子特徵選擇性地抑制癌細胞的生長或存活。隨著品牌標靶療法面臨專利到期，學名藥不斷湧現，以提供具有成本效益的替代方案，擴大個人化治療選擇的範圍。伴隨診斷與個人化醫療的整合日益受到重視。伴隨診斷有助於識別最有可能對特定治療產生反應的患者，使醫療保健提供者能夠根據患者獨特的基因譜量身定做治療干預措施。通用腫瘤藥物可以與伴隨診斷一起開發，以提高治療效果。

醫療保健成本控制

政府和醫療保健提供者越來越關注成本控制策略。使用非專利腫瘤藥物有助於降低整體醫療成本，使癌症治療對於醫療保健系統更具永續性。醫療保健（包括腫瘤治療）成本的不斷增加對於許多醫療保健系統來說變得不永續。此外，隨著癌症盛行率的上升和創新療法的出現，越來越需要尋找具有成本效益的解決方案。腫瘤學學名藥通常比品牌藥更便宜，在控制整體醫療保健支出方面發揮著至關重要的作用。政府和醫療保健支付者正在實施促進使用學名藥的政策，作為節省成本的措施。學名藥替代，即學名藥取代品牌藥，正積極鼓勵降低癌症治療的成本。在腫瘤學領域，這可以節省大量成本，特別是在處理高成本生物製劑時。學名藥的進入給品牌藥帶來了定價壓力。隨著學名藥替代品的出現，競爭往往會導致學名藥和品牌藥物的價格下降。這不僅有利於患者，也支持醫療保健成本控制措施。

對學名藥的接受度不斷提高

對學名藥的接受度不斷提高正在支持市場的成長。患者和醫療保健系統都受益於學名藥提供的經濟優勢，使基本藥物變得更便宜。臨床研究和現實世界的證據支持學名藥與品牌藥的表現相當的觀點。隨著越來越多的證據積累，醫療保健專業人員和患者對學名藥的有效性越來越有信心。學名藥的可用性正在擴展到各個治療領域，從心血管疾病和糖尿病等慢性疾病到急性疾病和傳染病。更廣泛的學名藥組合有助於提高接受度，因為它涵蓋了廣泛的醫療需求。除此之外，提高健康素養和教育患者了解學名藥的努力正在提高學名藥的接受度。當患者了解學名藥具有與品牌藥相同的品質和功效時，他們更有可能接受學名藥作為可行的治療選擇。此外，生物相似藥（高度相似的生物藥物版本）的出現正在得到各個地區的監管支持。這種支持增強了人們對生物相似藥安全性和有效性的信心，有助於它們作為昂貴生物製劑的替代品被接受。

市場整合與策略合作

併購正在成為尋求鞏固其在學名藥市場地位的公司的重要策略。大型製藥公司經常收購規模較小的製藥公司，以獲得其產品組合、製造能力或研究管道。此次合併提高了營運效率並增強了收購實體的整體競爭力。合作和夥伴關係使公司能夠匯集資源和專業知識，加速學名藥的研發 (R&D)。透過結合知識和利用優勢，公司可以更有效地將新的和改進的學名藥配方推向市場。這對於及時引入具有成本效益的替代方案至關重要的行業至關重要。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球學名藥市場

  • 市場概況
  • 市場業績
  • 市場區隔：按地區
  • 市場預測

第 6 章：全球學名藥市場

  • 市場概況
  • 市場走向
  • COVID-19 的影響
  • 頂級非專利腫瘤藥物
  • 價格分析
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
    • 研究與開發
    • 製造業
    • 行銷
    • 分配
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
    • 學名藥產業的法規
  • 主要市場促進因素與成功因素

第 7 章：全球學名藥市場：主要地區表現

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第 8 章：全球學名藥市場：競爭格局

  • 市場結構
  • 市場區隔：按關鍵參與者
  • 主要球員簡介

第 9 章：學名藥腫瘤藥物生產流程

  • 產品概述
  • 詳細製程（片劑）
  • 詳細製程（注射）
  • 涉及的各種類型的單元操作
  • 質量平衡和原料要求

第 10 章：專案細節、要求與涉及的成本

  • 土地需求和支出
  • 建設需求及支出
  • 工廠機械
  • 機械圖片
  • 原料需求及支出
  • 包裝要求及費用
  • 交通需求及支出
  • 公用事業要求和支出
  • 人手需求及開支
  • 其他資本投資

第 11 章：貸款與經濟援助

第 12 章：專案經濟學

  • 專案資本成本
  • 技術經濟參數
  • 供應鏈各層面的產品定價與利潤
  • 稅金和折舊
  • 收入預測
  • 支出預測
  • 財務分析
  • 利潤分析
Product Code: SR112024A545

The global generic oncology drugs market size reached US$ 29.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 45.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.98% during 2024-2032. The market is experiencing steady growth driven by the growing prevalence of cancer due to excessive smoking of tobacco products and consumption of alcohol, rising investments in research operations for developing novel drugs, and increasing implementation of stringent regulations for streamlining drug production process.

Generic Oncology Drugs Market Analysis:

Market Growth and Size: The generic oncology drugs market is experiencing stable growth, driven by the increasing cancer prevalence and the growing demand for cost-effective treatment options.

Major Market Drivers: Key drivers include the rising cancer prevalence, patent expirations of branded oncology drugs, government initiatives to control healthcare costs, and advancements in pharmaceutical manufacturing technologies.

Technological Advancements: Continuous innovations are leading to enhanced quality control, streamlined manufacturing processes, and improved formulation and delivery systems for generic oncology drugs.

Industry Applications: Generic oncology drugs are primarily used in cancer treatment across various cancer types, making them a vital component of cancer care. They offer cost-effective alternatives to branded drugs, increasing patient accessibility.

Key Market Trends: Key trends include the growing adoption of biosimilars in oncology, personalized medicine approaches, and the influence of telemedicine and remote healthcare services on drug delivery. These trends reflect evolving patient needs and healthcare practices.

Geographical Trends: The North America region exhibits significant growth in the generic oncology drugs market due to the high cancer prevalence, stringent regulatory frameworks, and emphasis on cost containment. Asia Pacific is also witnessing significant developments on account of rising investments in medical research operations.

Competitive Landscape: The market features a competitive landscape with multiple pharmaceutical companies actively engaged in research and development (R&D) and manufacturing of generic oncology drugs. Strategic partnerships and acquisitions are common strategies to strengthen market positions.

Challenges and Opportunities: Challenges include navigating complex regulatory processes, ensuring product quality and safety, and addressing competition. However, these challenges also present opportunities for expanding product portfolios, meeting the demand for personalized cancer treatments, and entering emerging markets with unmet healthcare needs. Overall, the market presents significant growth potential for players who can navigate these challenges effectively.

Generic Oncology Drugs Market Trends:

Increasing Cases of Cancer

The increasing cases of cancer around the world represent one of the crucial factors impelling the growth of the market. This rise in cancer diagnoses is leading to a series of developments and transformations within the pharmaceutical industry, particularly in the domain of generic oncology drugs. These transformations, driven by the heightened cancer incidence, are multifaceted and have far-reaching implications that contribute to the accessibility and effectiveness of generic oncology drugs. With cancer emerging as a leading cause of morbidity and mortality, the availability of cost-effective and reliable treatment options is paramount. Generic oncology drugs, often more affordable than their branded counterparts, are ideally positioned to meet this demand and provide accessible solutions for patients across diverse socioeconomic backgrounds. Their affordability and accessibility make them indispensable tools in the fight against cancer, ensuring that patients receive timely and adequate care. This alleviation of healthcare system pressures enhances the overall efficiency and effectiveness of cancer treatment, ultimately benefiting patients.

Government Initiatives and Regulations

Government regulatory agencies oversee the approval and market entry of generic oncology drugs. They establish rigorous standards to evaluate the safety and efficacy of these medications before granting approval. These standards are critical in ensuring that generic drugs are reliable and effective alternatives to their branded counterparts. Government policies related to patent expiration and market exclusivity periods significantly impact the availability of generic oncology drugs. When patents for branded oncology drugs expire, regulatory agencies may grant approval for generic versions to enter the market. This process is guided by legal frameworks, which encourage competition and affordability in the pharmaceutical industry. Regulatory agencies oversee pharmacovigilance programs to monitor and assess the safety of generic oncology drugs once they are on the market. These agencies also enforce quality control standards to maintain the consistent quality and purity of medications, ensuring that patients receive safe and effective treatments. Moreover, governing agencies of various countries are providing incentives, such as research grants or tax benefits, to encourage pharmaceutical companies to invest in the development of generic oncology drugs.

Technological Advancements in Manufacturing

The rising advancements in the manufacturing of generic oncology drugs are supporting the market growth. Advanced manufacturing technologies, such as continuous manufacturing and real-time monitoring systems, are improving the quality control of generic oncology drugs. These systems enable pharmaceutical companies to maintain consistent product quality, reducing the risk of variations that can impact patient outcomes. This enhanced quality assurance instils confidence in the effectiveness of generic drugs. Automation and robotics are streamlining the manufacturing processes of generic oncology drugs. This increased efficiency results in higher production volumes, reduced production costs, and faster time-to-market for these medications. Technological advancements are also expanding the scalability of manufacturing operations. This is enabling generic oncology drug manufacturers to adjust production volumes more flexibly in response to market demand. Advances in drug formulation and delivery systems are facilitating the development of innovative generic oncology drug products. These technologies have the potential to enhance drug efficacy, reduce side effects, and improve patient compliance, all of which are critical factors in cancer treatment.

Patent Expirations and Cost-Effective Solutions

Patent expirations of several branded oncology drugs are opening opportunities for generic drug manufacturers. When patents for innovative cancer therapies expire, generic manufacturers can enter the market, offering lower-cost alternatives. This competition not only reduces the financial burden on patients but also contributes to healthcare cost containment. The availability of affordable generic oncology drugs ensures that more patients can access treatment, thereby fueling market growth.

Regulatory Support and Approval Pathways

Regulatory bodies are implementing expedited approval pathways for generic oncology drugs. Additionally, various government initiatives and policies encourage the development and manufacturing of generic oncology drugs. These regulatory supports create a favorable environment for generic drug manufacturers. Some regulatory agencies are also offering expedited pathways for the review and approval of generic oncology drugs, especially when there is a need for increased competition or when the drug in question addresses an unmet medical need. These pathways aim to streamline the approval process and facilitate timely market entry. Generic drug manufacturers may face patent challenges from innovator companies seeking to extend their exclusivity. Patent litigation and challenges play a role in the regulatory landscape, as the resolution of patent disputes can influence the timing of generic market entry.

Demand for Personalized Medicine

Advances in genomics and biomarker research are enabling a deeper understanding of the molecular mechanisms underlying cancer. This knowledge allows for the identification of specific genetic alterations and biomarkers associated with different types of cancer, paving the way for the development of targeted therapies. Personalized medicine in oncology often involves the use of targeted therapies designed to selectively inhibit cancer cell growth or survival based on specific molecular characteristics. As branded targeted therapies face patent expirations, generic equivalents are emerging to provide cost-effective alternatives, expanding access to personalized treatment options. The integration of companion diagnostics with personalized medicine is gaining prominence. Companion diagnostics help identify patients who are most likely to respond to a particular treatment, allowing healthcare providers to tailor therapeutic interventions based on the unique genetic profile of patients. Generic oncology drugs can be developed in tandem with companion diagnostics to enhance treatment efficacy.

Healthcare Cost Containment

Governments and healthcare providers are increasingly focusing on cost containment strategies. The use of generic oncology drugs helps in reducing overall healthcare costs, making cancer treatment more sustainable for healthcare systems. The increasing cost of healthcare, including oncology treatments, is becoming unsustainable for many healthcare systems. Moreover, as cancer prevalence rises and innovative therapies emerge, there is a growing need to find cost-effective solutions. Generic oncology drugs, often more affordable than their branded counterparts, play a crucial role in containing overall healthcare expenditures. Governments and healthcare payers are implementing policies promoting the use of generic drugs as a cost-saving measure. Generic substitution, where generic drugs replace branded ones, is actively encouraging to drive down the cost of cancer treatments. In the oncology sector, this can lead to significant savings, especially when dealing with high-cost biologics. The entry of generic oncology drugs creates pricing pressures on branded drugs. As generic alternatives become available, the competition often results in reduced prices for both generic and branded medications. This not only benefits patients but also supports healthcare cost containment initiatives.

Rising Acceptance of Generics

The rising acceptance of generics is supporting the growth of the market. Patients and healthcare systems alike benefit from the economic advantages offered by generic drugs, making essential medications more affordable. Clinical studies and real-world evidence support the notion that generic drugs perform comparably to brand-name drugs. As more evidence accumulates, healthcare professionals and patients become increasingly confident in the effectiveness of generic medications. The availability of generic versions is expanding across various therapeutic areas, ranging from chronic conditions like cardiovascular diseases and diabetes to acute conditions and infectious diseases. A broader generic drug portfolio contributes to increased acceptance as it covers a wide range of medical needs. Apart from this, efforts to enhance health literacy and educate patients about generic medications are increasing acceptance of generics. When patients understand that generics offer the same quality and efficacy as brand-name drugs, they are more likely to accept them as viable treatment options. Furthermore, the emergence of biosimilars, which are highly similar versions of biologic drugs, is receiving regulatory support in various regions. This support boosts confidence in the safety and efficacy of biosimilars, contributing to their acceptance as alternatives to expensive biologics.

Market Consolidation and Strategic Collaborations

Mergers and acquisitions are becoming prominent strategies for companies seeking to consolidate their positions in the generic oncology drugs market. Large pharmaceutical companies often acquire smaller players to gain access to their product portfolios, manufacturing capabilities, or research pipelines. This consolidation enhances operational efficiency and strengthens the overall competitiveness of the acquiring entity. Collaborations and partnerships allow companies to pool resources and expertise, accelerating the research and development (R&D) of generic oncology drugs. By combining knowledge and leveraging strengths, companies can bring new and improved generic formulations to market more efficiently. This is crucial in a sector where timely introduction of cost-effective alternatives is essential.

Generic Oncology Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America leads the market, accounting for the largest generic oncology drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The North America generic oncology drug market is largely driven by the rising prevalence of cancer among the masses due to excessive consumption of alcohol and smoking tobacco products. Governing bodies and healthcare providers in the region are increasingly focused on containing healthcare costs. Generic oncology drugs, known for their cost-effectiveness, align with this goal and are preferred options in various healthcare systems. Stringent regulatory frameworks are governing and streamlining the approval of generic drugs. These regulations ensure the safety, efficacy, and quality of generic oncology drugs, instilling confidence among healthcare professionals and patients. Additionally, technological advancements in pharmaceutical manufacturing, such as continuous manufacturing and automation, are improving the efficiency and cost-effectiveness of producing generic oncology drugs.

Asia Pacific stands as another key region in the market, driven by the increasing investments to improve healthcare infrastructure, increase access to essential medicines, and control healthcare costs. The promotion of generic medications, including oncology drugs, is often a key component of these initiatives to make cancer treatment more affordable. The overall increase in healthcare expenditure in the Asia-Pacific region is leading to a greater emphasis on cost containment. Generic oncology drugs, being more affordable than their branded counterparts, are integral to managing the economic impact of cancer care.

Leading Key Players in the Generic Oncology Drugs Industry:

Key players in the generic oncology drugs market are actively engaged in various strategic initiatives to maintain and expand their market presence. These initiatives include the development and launch of new generic oncology drugs, often following the expiration of patents for branded medications. Additionally, top companies are investing in research and development (R&D) to enhance the quality and efficacy of their generic oncology drug offerings. They are also focusing on cost-efficient manufacturing processes, leveraging technological advancements to improve production efficiency. Marketing efforts emphasize the affordability and accessibility of their products to both patients and healthcare systems. Furthermore, strategic partnerships, collaborations, and acquisitions are becoming prevalent as companies seek to strengthen their portfolios and global reach in this competitive market. Leading companies are actively involving in developing and commercializing generic versions of various oncology medications. They are also prioritizing on biosimilars, including biosimilar versions of oncology drugs and involving in the development and commercialization of cost-effective alternatives to branded oncology biologics.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided.

Key Questions Answered in This Report

  • 1. What was the size of the global generic oncology drugs market in 2023?
  • 2. What is the expected growth rate of the global generic oncology drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global generic oncology drugs market?
  • 4. What are the key factors driving the global generic oncology drugs market?
  • 5. What are the key regions in the global generic oncology drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drug Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Breakup by Region
  • 5.4 Market Forecast

6 Global Generic Oncology Drug Market

  • 6.1 Market Overview
  • 6.2 Market Trends
  • 6.3 Impact of COVID-19
  • 6.4 Top Generic Oncology Drugs
  • 6.5 Price Analysis
  • 6.6 Market Forecast
  • 6.7 SWOT Analysis
    • 6.7.1 Overview
    • 6.7.2 Strengths
    • 6.7.3 Weaknesses
    • 6.7.4 Opportunities
    • 6.7.5 Threats
  • 6.8 Value Chain Analysis
    • 6.8.1 Research and Development
    • 6.8.2 Manufacturing
    • 6.8.3 Marketing
    • 6.8.4 Distribution
  • 6.9 Porter's Five Forces Analysis
    • 6.9.1 Overview
    • 6.9.2 Bargaining Power of Buyers
    • 6.9.3 Bargaining Power of Suppliers
    • 6.9.4 Degree of Competition
    • 6.9.5 Threat of New Entrants
    • 6.9.6 Threat of Substitutes
    • 6.9.7 Regulations in the Generics Industry
  • 6.10 Key Market Drivers and Success Factors

7 Global Generic Oncology Drug Market: Performance of Key Regions

  • 7.1 North America
  • 7.2 Europe
  • 7.3 Asia Pacific
  • 7.4 Middle East and Africa
  • 7.5 Latin America

8 Global Generic Oncology Drug Market: Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Market Breakup by Key Players
  • 8.3 Key Player Profiles

9 Generic Oncology Drug Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Detailed Process Flow (Tablets)
  • 9.3 Detailed Process Flow (Injectable)
  • 9.4 Various Types of Unit Operations Involved
  • 9.5 Mass Balance and Raw Material Requirements

10 Project Details, Requirements and Costs Involved

  • 10.1 Land Requirements and Expenditures
  • 10.2 Construction Requirements and Expenditures
  • 10.3 Plant Machinery
  • 10.4 Machinery Pictures
  • 10.5 Raw Material Requirements and Expenditures
  • 10.6 Packaging Requirements and Expenditures
  • 10.7 Transportation Requirements and Expenditures
  • 10.8 Utility Requirements and Expenditures
  • 10.9 Manpower Requirements and Expenditures
  • 10.10 Other Capital Investments

11 Loans and Financial Assistance

12 Project Economics

  • 12.1 Capital Cost of the Project
  • 12.2 Techno-Economic Parameters
  • 12.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 12.4 Taxation and Depreciation
  • 12.5 Income Projections
  • 12.6 Expenditure Projections
  • 12.7 Financial Analysis
  • 12.8 Profit Analysis

List of Figures

  • Figure 1: Global: Generic Drug Market: Major Drivers and Challenges
  • Figure 2: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2018-2023
  • Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2024-2032
  • Figure 4: Global: Generic Drug Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Generic Oncology Drug Industry Overview
  • Figure 6: Global: Generic Oncology Drug Market: Sales Value Trends (in Billion US$), 2018-2023
  • Figure 7: Global: Generic Oncology Drug Market Forecast: Sales Value Trends (in Billion US$), 2024-2032
  • Figure 8: Global: Generic Oncology Drug Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Generic Oncology Drug Industry: SWOT Analysis
  • Figure 10: Global: Generic Oncology Drug Industry: Value Chain Analysis
  • Figure 11: Global: Generic Oncology Drug Industry: Porter's Five Forces Analysis
  • Figure 12: North America: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 13: Asia Pacific: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 14: Europe: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 15: Latin America: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 16: Middle East and Africa: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 17: Generic Oncology Drug Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 18: Generic Oncology Drug Manufacturing: Production Cost Breakup (in %)
  • Figure 19: Generic Oncology Drug Manufacturing Plant: Detailed Process Flow
  • Figure 20: Generic Oncology Drug Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 21: Generic Oncology Drug Manufacturing Plant: Proposed Plant Layout
  • Figure 22: Generic Oncology Drug Manufacturing Plant: Breakup of Capital Costs (in %)

List of Tables

  • Table 1: Global: Generic Drug Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Generic Drug Market Forecast: Breakup by Region, 2024-2032
  • Table 3: Global: Generic Oncology Drug Market: Key Industry Highlights, 2023 and 2032
  • Table 4: Generic Oncology Drug Manufacturing Plant: Costs Related to Land and Site Development (in US$)
  • Table 5: Generic Oncology Drug Manufacturing Plant: Costs Related to Civil Works (in US$)
  • Table 6: Generic Oncology Drug Manufacturing Plant: Costs Related to Machinery Unit (in US$)
  • Table 7: Generic Oncology Drug Manufacturing Plant: Raw Material Requirements
  • Table 8: Generic Oncology Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
  • Table 9: Generic Oncology Drug Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
  • Table 10: Details of Financial Assistance Offered by Financial Institutions
  • Table 11: Generic Oncology Drug Manufacturing Plant: Capital Costs (in US$)
  • Table 12: Generic Oncology Drug Manufacturing Plant: Techno-Economic Parameters
  • Table 13: Generic Oncology Drug Manufacturing Plant: Taxation and Depreciation
  • Table 14: Generic Oncology Drug Manufacturing Plant: Income Projections (in US$)
  • Table 15: Generic Oncology Drug Manufacturing Plant: Expenditure Projections (in US$)
  • Table 16: Generic Oncology Drug Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability
  • Table 17: Generic Oncology Drug Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability
  • Table 18: Generic Oncology Drug Manufacturing Plant: Profit and Loss Account